MedPath

Supplementary Motor Area is a Potential Target for Speech Disturbance in Parkinson Disease

Not Applicable
Not yet recruiting
Conditions
Parkinson Disease
Interventions
Device: "MAGSTIM" Repetitive transcranial magnetic stimulator (rTMS) system
Registration Number
NCT05478057
Lead Sponsor
Chang Gung Memorial Hospital
Brief Summary

Speech disturbance is common in patients with Parkinson disease. Pharmacotherapy improves motor symptoms but has inconsistent effects on speech disturbance in PD patients. Transcranial magnetic stimulation (TMS) is a safe and non-invasive tool used for brain stimulation. Repetitive transcranial magnetic stimulation (rTMS) has positive effects on motor function of PD. Yet, its effect on speech disturbance seems to be inconclusive. Previous rTMS studies mainly focused on the primary motor cortex for PD speech disturbance. Nevertheless, we think supplementary motor area (SMA) may be a better target. Speech disturbance in PD may be associated with basal ganglia-thalamocortical motor circuits and SMA involves in the cortex part. In addition, neuroimaging studies showed that SMA were under-activation in PD patients. Therefore, we conduct this 3-year study including two experiments. The aim of the study is to determine if rTMS over SMA can improve the speech function of PD patients and change the functional connectivity of speech pathway in the brain. This will be the first study to investigate the effect of rTMS over SMA on speech.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • right-handed healthy adult volunteers who understand and agree on the informed consent of the study
Exclusion Criteria
  • pregnancy or possibility of pregnancy
  • history of seizure
  • family history of epilepsy
  • metals in any part of the body.

Experiment 2

Inclusion Criteria:

  • PD patients with speech disturbance who understand and agree on the informed consent of the study. The speech item scored 2 or 3 in the unified Parkinson's disease rating scale (UPDRS) part III.

Exclusion Criteria:

  • dementia
  • the history of stroke, brain lesion, other central nervous system diseases
  • the contraindication of TMS which described above
  • any contraindication of MRI

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PD patients without speech disturbance treated with 10 Hz rTMS"MAGSTIM" Repetitive transcranial magnetic stimulator (rTMS) system-
PD patients with speech disturbance treated with sham rTMS"MAGSTIM" Repetitive transcranial magnetic stimulator (rTMS) system-
PD patients without speech disturbance with sham rTMS"MAGSTIM" Repetitive transcranial magnetic stimulator (rTMS) system-
PD patients with speech disturbance treated with 10 Hz rTMS"MAGSTIM" Repetitive transcranial magnetic stimulator (rTMS) system-
Primary Outcome Measures
NameTimeMethod
Change of speech performance from baseline in experiment 1Baseline ((1) before rTMS), (2) immediately after rTMS

1. sustained phonation of /a/ for as long and steady as possible in one breath

2. fast pa-/ta-/ka- repetition at least nine times in one breath

3. reading a standardized paragraph composed of 80 words as clear and fast as possible

Change of functional connectivity from baseline in experiment 2Baseline ((1) before rTMS), (2) within 24 hours after 10 times of rTMS

use rs-fMRI to compare the functional connectivity between PD patients with and without speech disturbance and the changes of connectivity after rTMS over SMA

Change of speech performance from baseline in experiment 2Baseline ((1) before rTMS), (2) within 24 hours after 10 times of rTMS (3) 8 weeks later after 10 times of rTMS

1. sustained phonation of /a/ for as long and steady as possible in one breath

2. fast pa-/ta-/ka- repetition at least nine times in one breath

3. reading a standardized paragraph composed of 80 words as clear and fast as possible

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath